250 related articles for article (PubMed ID: 18369820)
1. Telomerase RNA inhibition using antisense oligonucleotide against human telomerase RNA linked to a 2',5'-oligoadenylate.
Kondo Y; Kondo S
Methods Mol Biol; 2007; 405():97-112. PubMed ID: 18369820
[TBL] [Abstract][Full Text] [Related]
2. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas.
Mukai S; Kondo Y; Koga S; Komata T; Barna BP; Kondo S
Cancer Res; 2000 Aug; 60(16):4461-7. PubMed ID: 10969793
[TBL] [Abstract][Full Text] [Related]
3. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells.
Yatabe N; Kyo S; Kondo S; Kanaya T; Wang Z; Maida Y; Takakura M; Nakamura M; Tanaka M; Inoue M
Cancer Gene Ther; 2002 Jul; 9(7):624-30. PubMed ID: 12082463
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA.
Kondo S; Kondo Y; Li G; Silverman RH; Cowell JK
Oncogene; 1998 Jun; 16(25):3323-30. PubMed ID: 9681832
[TBL] [Abstract][Full Text] [Related]
5. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells.
Kushner DM; Paranjape JM; Bandyopadhyay B; Cramer H; Leaman DW; Kennedy AW; Silverman RH; Cowell JK
Gynecol Oncol; 2000 Feb; 76(2):183-92. PubMed ID: 10637068
[TBL] [Abstract][Full Text] [Related]
6. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA.
Koga S; Kondo Y; Komata T; Kondo S
Gene Ther; 2001 Apr; 8(8):654-8. PubMed ID: 11320413
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.
Komata T; Kondo Y; Koga S; Ko SC; Chung LW; Kondo S
Gene Ther; 2000 Dec; 7(24):2071-9. PubMed ID: 11223987
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
Iwado E; Daido S; Kondo Y; Kondo S
Int J Oncol; 2007 Nov; 31(5):1087-95. PubMed ID: 17912434
[TBL] [Abstract][Full Text] [Related]
9. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component.
Kondo Y; Koga S; Komata T; Kondo S
Oncogene; 2000 Apr; 19(18):2205-11. PubMed ID: 10822370
[TBL] [Abstract][Full Text] [Related]
10. Telomerase inhibition by synthetic nucleic acids and chemosensitization in human bladder cancer cell lines.
Kraemer K; Fuessel S; Meye A
Methods Mol Biol; 2007; 405():9-22. PubMed ID: 18369813
[TBL] [Abstract][Full Text] [Related]
11. Antisense human telomerase reverse transcriptase could partially reverse malignant phenotypes of gastric carcinoma cell line in vitro.
Yang SM; Fang DC; Yang JL; Chen L; Luo YH; Liang GP
Eur J Cancer Prev; 2008 Jun; 17(3):209-17. PubMed ID: 18414191
[TBL] [Abstract][Full Text] [Related]
12. Correlation of selective modifications to a 2',5'-oligoadenylate-3',5'-deoxyribonucleotide antisense chimera with affinity for the target nucleic acid and with ability to activate RNase L.
Xiao W; Li G; Maitra RK; Maran A; Silverman RH; Torrence PF
J Med Chem; 1997 Apr; 40(8):1195-200. PubMed ID: 9111293
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of telomerase with human telomerase reverse transcriptase antisense enhances tumor necrosis factor-alpha-induced apoptosis in bladder cancer cells.
Gao XD; Chen YR
Chin Med J (Engl); 2007 May; 120(9):755-60. PubMed ID: 17531113
[TBL] [Abstract][Full Text] [Related]
14. Human telomerase RNA degradation by 2'-5'-linked oligoadenylate antisense chimeras in a cell-free system, cultured tumor cells, and murine xenograft models.
Paranjape JM; Xu D; Kushner DM; Okicki J; Lindner DJ; Cramer H; Silverman RH; Leaman DW
Oligonucleotides; 2006; 16(3):225-38. PubMed ID: 16978086
[TBL] [Abstract][Full Text] [Related]
15. Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells.
Wong SC; Yu H; Moochhala SM; So JB
Anticancer Res; 2003; 23(1A):465-9. PubMed ID: 12680250
[TBL] [Abstract][Full Text] [Related]
16. Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro.
Schindler A; Fiedler U; Meye A; Schmidt U; Füssel S; Pilarsky C; Herrmann J; Wirth MP
Int J Oncol; 2001 Jul; 19(1):25-30. PubMed ID: 11408918
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells.
Folini M; Brambilla C; Villa R; Gandellini P; Vignati S; Paduano F; Daidone MG; Zaffaroni N
Eur J Cancer; 2005 Mar; 41(4):624-34. PubMed ID: 15737568
[TBL] [Abstract][Full Text] [Related]
18. [Cleavage of telomerase RNA component by two DNAzymes and their effects on expression of two apoptosis-related genes in human mammary cancer cells].
Zhao JM; Li MY; Yang Z; Li Z; Zhang Y
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):638-42. PubMed ID: 15958297
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides.
Glukhov AI; Zimnik OV; Gordeev SA; Severin SE
Biochem Biophys Res Commun; 1998 Jul; 248(2):368-71. PubMed ID: 9675142
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of telomerase with human telomerase reverse transcriptase antisense increases the sensitivity of tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells.
Gao XD; Chen YR
Asian J Androl; 2007 Sep; 9(5):697-704. PubMed ID: 17712489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
